ClinicalTrials.gg
Not yet recruitingNCT07310082Updated Oct 26, 2026

Allograft vs. Autograft Nonunion

An interventional study of Autograft and Allograft in Nonunion Fracture, sponsored by Wake Forest University Health Sciences. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Treatment

Updated Oct 26, 2026Start date movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this research study is to find out if patients treated for nonunion fracture with autograft or allograft return to activity faster.

Read the detailed description

The goal of this multi-center prospective randomized controlled trial is to compare short and long-term outcomes of adult patients with long-bone nonunion treated with autograft versus allograft. The main question it aims to answer is: will patients who receive an allograft return to work faster than patients who receive an autograft to treat nonunion fracture.

Participants will be randomized to one of two treatment groups and will complete follow-up surveys during their recovery.

02

Conditions studied

  • Nonunion Fracture

Browse trials for

Keywords

  • Allograft
  • Autograft
  • Nonunion
03

In context

Fractures, Ununited

43 studies on the registry are indexed under Fractures, Ununited; 10 are open to participants now.

This study's planned enrollment of 156 is above the median of 60 across 27 interventional studies indexed under Fractures, Ununited.

Browse Fractures, Ununited studies →

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,351 studies on the registry; 201 are open to participants now.

Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years or older
  • Long bone (tibia, femur, and humerus) nonunion appropriate for either study treatment: to be treated with bone graft harvested from a remote site or using reamer harvester (RIA)
  • Nonunion surgery to be performed at least five months after initial fracture fixation
  • Prior operative fixation of fracture
  • Radiographic apparent bone gap (RABG) of >5cm

Exclusion criteria

Exclusion Criteria:

  • Patient that speaks neither English nor Spanish
  • Patients whose treatment plan includes local autograft only (available callus from the nonunion site or no planned bone graft)
  • Known active infection (defined as any clinical signs or symptoms of active infection, such as fevers, wound redness, warmth, swelling, induration or drainage, and abnormal while blood cell count, erythrocyte sedimentation rate, or C-reactive protein) being treated with antibiotics
  • greater than 50
  • Patients unlikely to follow-up due to homelessness, or planning follow-up at another institution
  • Prisoner
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • Active comparator
    Autograft

    Patients randomized to autograft

    Procedure: Autograft

  • Active comparator
    Allograft

    Patients randomized to allograft.

    Procedure: Allograft

Interventions

  • ProcedureAutograft

    Surgeons will decide on the location and method of donor site based on the clinical situation. Most commonly, bone graft will be harvested from the anterior or posterior iliac crest or utilizing the Reamer Irrigator Aspirator in an appropriate long bone. Surgeons may choose to harvest autograft from proximal tibia or distal femur. Donor site location is at the discretion of treating surgeon for patients who randomize to autograft. This treatment arm will not include local autograft only. For large bone defects requiring expansion of autograft with allograft, this will be allowed and recorded. We will use intent-to-treat for statistical analysis of those with allograft expansion of autograft. This autograft will be applied to the nonunion site using the surgeon's typical technique. Internal fixation, revision of fixation, and/or augmentation of fixation will be performed at the discretion of the surgeon.

  • ProcedureAllograft

    Allograft bone will consist of cancellous or corticocancellous sterile packaged human cadaveric bone. No bone morphogenetic protein, bone marrow aspirate, or other biologic augment will be added. Demineralized bone matrix may be added at the surgeon's discretion. This allograft will be applied to the nonunion site using the surgeon's typical technique. Internal fixation, revision of fixation, and/or augmentation of fixation will be performed at the discretion of the surgeon.

06

What researchers measure

Primary outcomes

  1. Metabolic Equivalent for Tasks Score

    Time to return to work/duty will be measured using the the International Physical Activity Questionnaire (IPAQ).The IPAQ is a validated, self-report measure that captures detailed information about participation in a wide range of physical activities, including the number of days and amount of time spent in the previous 7 days. Responses for each type of physical activity are then transformed into the number of Metabolic Equivalent for Tasks (METs), and a METs/week is calculated for each patient.

    Time frame: Week 6

  2. Metabolic Equivalent for Tasks Score

    Time to return to work/duty will be measured using the the International Physical Activity Questionnaire (IPAQ).The IPAQ is a validated, self-report measure that captures detailed information about participation in a wide range of physical activities, including the number of days and amount of time spent in the previous 7 days. Responses for each type of physical activity are then transformed into the number of Metabolic Equivalent for Tasks (METs), and a METs/week is calculated for each patient.

    Time frame: Month 3

  3. Metabolic Equivalent for Tasks Score

    Time to return to work/duty will be measured using the the International Physical Activity Questionnaire (IPAQ).The IPAQ is a validated, self-report measure that captures detailed information about participation in a wide range of physical activities, including the number of days and amount of time spent in the previous 7 days. Responses for each type of physical activity are then transformed into the number of Metabolic Equivalent for Tasks (METs), and a METs/week is calculated for each patient.

    Time frame: Month 6

  4. Metabolic Equivalent for Tasks Score

    Time to return to work/duty will be measured using the the International Physical Activity Questionnaire (IPAQ).The IPAQ is a validated, self-report measure that captures detailed information about participation in a wide range of physical activities, including the number of days and amount of time spent in the previous 7 days. Responses for each type of physical activity are then transformed into the number of Metabolic Equivalent for Tasks (METs), and a METs/week is calculated for each patient.

    Time frame: Month 12

  5. Average Time to Return to Work/Duty

    Average number of days it takes for participants to return to work/duty

    Time frame: Week 6

  6. Average Time to Return to Work/Duty

    Average number of days it takes for participants to return to work/duty

    Time frame: Month 3

  7. Average Time to Return to Work/Duty

    Average number of days it takes for participants to return to work/duty

    Time frame: Month 6

  8. Average Time to Return to Work/Duty

    Average number of days it takes for participants to return to work/duty

    Time frame: Month 12

  9. Number of Participants Returned to Work

    Determined by asking whether subjects have returned to work

    Time frame: Week 6

  10. Number of Participants Returned to Work

    Determined by asking whether subjects have returned to work

    Time frame: Month 3

  11. Number of Participants Returned to Work

    Determined by asking whether subjects have returned to work

    Time frame: Month 6

  12. Number of Participants Returned to Work

    Determined by asking whether subjects have returned to work

    Time frame: Month 12

Secondary outcomes

  1. Percentage of Union

    Percentage of union will be assessed via radiographs and determined by the treating surgeon.

    Time frame: Week 6, Month 3, Month 6, Month 12

  2. Time to Union

    Number of days to union

    Time frame: Week 6, Month 3, Month 6, Month 12

  3. Radiographic Union Scale in Tibial fractures (RUST) score

    The RUST score ranges from a minimum score of 4 (definitely not healed) to a maximum score of 12 (completely healed). The final x-ray obtained within a 12-month period following injury will be uploaded to REDCap for review by a blinded panel of investigators from participating sites.

    Time frame: Month 12

  4. Number of Participants who Return to the Operating Room

    Number of participants who return to the Operating Room after procedure

    Time frame: Week 6, Month 3, Month 6, Month 12

  5. PROMIS-29 Subscale - Physical Function

    The PROMIS-29 scales will be scored using a T-score metric method. A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Higher scores means higher physical function.

    Time frame: Week 6, Month 3, Month 6, Month 12

  6. PROMIS-29 Subscale - Anxiety

    The PROMIS-29 scales will be scored using a T-score metric method. A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Higher scores means a higher level of anxiety.

    Time frame: Week 6, Month 3, Month 6, Month 12

  7. PROMIS-29 Subscale - Depression

    The PROMIS-29 scales will be scored using a T-score metric method. A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Higher scores means a higher level of depression

    Time frame: Week 6, Month 3, Month 6, Month 12

  8. PROMIS-29 Subscale - Fatigue

    The PROMIS-29 scales will be scored using a T-score metric method. A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Higher scores means a higher level of fatigue.

    Time frame: Week 6, Month 3, Month 6, Month 12

  9. PROMIS-29 Subscale - Sleep Disturbance

    The PROMIS-29 scales will be scored using a T-score metric method. A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Higher scores means a higher level of sleep disturbance.

    Time frame: Week 6, Month 3, Month 6, Month 12

  10. PROMIS-29 Subscale - Pain Interference

    The PROMIS-29 scales will be scored using a T-score metric method. A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Higher scores means a higher level of pain interference.

    Time frame: Week 6, Month 3, Month 6, Month 12

  11. PROMIS-29 Subscale - Ability to Participate in Social Roles and Activities

    The PROMIS-29 scales will be scored using a T-score metric method. A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Higher scores means a higher ability to participate in social roles and activities.

    Time frame: Week 6, Month 3, Month 6, Month 12

  12. Number of Resource Utilizations

    Healthcare utilization, including new hospitalizations, emergency department visits, clinic visits, imaging, and physical therapy sessions will be documented at all follow-up visits

    Time frame: Week 6, Month 3, Month 6, Month 12

  13. Pain Intensity Scores

    Pain will be assessed using the Brief Pain Inventory (BPI). The BPI is a commonly used and validated 15-item measure of pain intensity and interference with daily life. Worst pain score 1-4 = mild pain, 5-6 = moderate pain, 7-10 = severe pain.

    Time frame: Week 6, Month 3, Month 6, Month 12

  14. Veterans RAND 12 Item Health Survey (VR-12) Scores

    The VR-12 is a measure of global health that correspond to seven domains: general health, physical functioning, role limitations, pain, fatigue, social functioning, and mental health. Together, these items are summarized into a Physical Component Score and a Mental Component Score. Scores range from 0-100 with higher scores indicating better physical and mental health functioning.

    Time frame: Week 6, Month 3, Month 6, Month 12

  15. Work Productivity and Activity Impairment Questionnaire Scores

    Participants who report return to work/duty will complete the Work Productivity and Activity Impairment Questionnaire, a validated instrument that measures work time missed and work and activity impairment due to health problems. Measures absenteeism, presenteeism as well as the impairments in unpaid activity because of health problem during the past seven days. The higher number of day equates to more health problems.

    Time frame: Week 6, Month 3, Month 6, Month 12

  16. Number of Complications

    Number of major complications, including infection, implant failure, unplanned or planned return to the operating room related to the nonunion procedure, deep venous thrombosis, or pulmonary embolism.

    Time frame: Week 6, Month 3, Month 6, Month 12

07

Study locations

1 site
  • Atrium Health Carolinas Medical Center
    Charlotte, North Carolina 28203, United States
    • Rachel B Seymour, PhD · ContactRachel.Seymour@advocatehealth.org · 704-441-5365
    • Christine Churchill, MA · ContactChristine.Churchill@advocatehealth.org
    • Madhav Karunakar, MD · Sub investigator
    • Laurence Kempton, MD · Sub investigator
    • Suman Medda, MD · Sub investigator
    • Kevin Phelps, MD · Sub investigator
    • Sarah Pierrie, MD · Sub investigator
    • Sophia Traven, MD · Sub investigator
    • Rachel B Seymour, PhD · Sub investigator
    • Meghan Wally, PhD · Sub investigator
    • Garrett Bullock, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Start date
Oct 2026→Jan 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Start date Oct 2026→Jan 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07310082
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Jan 2027 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

Christine Churchill
Contact
Christine.Churchill@advocatehealth.org
704-355-6947
Joseph R Hsu, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion